Rhythm Biosciences Ltd. (AU:RHY) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Rhythm Biosciences Ltd has acquired the Genetype genetic risk assessment business assets, enhancing its oncology portfolio and offering immediate revenue opportunities. This strategic move is expected to diversify Rhythm’s capabilities and accelerate growth by leveraging Genetype’s existing customer base and skilled workforce in Australia and the USA. The integration of Genetype’s proteomic and genomic technologies promises to expand Rhythm’s market reach and boost shareholder returns.
For further insights into AU:RHY stock, check out TipRanks’ Stock Analysis page.